Welcome to our dedicated page for Pyxis Oncology SEC filings (Ticker: PYXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pyxis Oncology, Inc. (PYXS) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company focused on antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, Pyxis Oncology uses its SEC reports to describe clinical progress, financial condition, governance matters, and material corporate events.
Investors can review Form 8-K filings that summarize significant developments such as preliminary Phase 1 data for micvotabart pelidotin (MICVO) in recurrent and metastatic head and neck squamous cell carcinoma, updates on ongoing monotherapy and combination studies, royalty and milestone transactions related to licensed antibodies, and key financial or corporate announcements. These current reports often incorporate or reference company press releases and presentations that detail MICVO’s clinical performance, safety profile, and translational findings.
In addition to 8-Ks, users can consult Pyxis Oncology’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more comprehensive discussions of research and development activities, cash resources and runway expectations, collaboration agreements, and risk factors relevant to its oncology programs. Proxy materials and meeting results, such as submissions under Item 5.07 for stockholder votes, provide insight into board composition and corporate governance.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify disclosures related to MICVO’s clinical trials, Fast Track Designation, collaboration with Merck on pembrolizumab combinations, and financial arrangements involving royalty streams from antibodies discovered on the APXiMAB platform. Real-time updates from EDGAR, along with structured access to forms such as 10-K, 10-Q, 8-K, and other relevant submissions, allow users to follow how Pyxis Oncology reports its oncology development and corporate trajectory over time.
Pyxis Oncology is asking stockholders to vote at its 2026 virtual annual meeting on June 15, 2026. The proxy seeks approval to elect three Class II directors (Thomas Civik, Freda Lewis‑Hall, M.D., and Michael A. Metzger) and to ratify Ernst & Young LLP as auditor for 2026.
Stockholders of record as of April 20, 2026, holding 62,855,464 outstanding common shares in aggregate, are entitled to vote online, by phone, mail, or during the live webcast after registering at proxydocs.com/PYXS.
Pyxis Oncology, Inc. filed an amendment to outline the separation terms for Lara Sullivan, M.D., whose service as Chief Executive Officer and principal executive officer ended earlier in 2026. The filing also notes that she resigned from the Board of Directors on April 29, 2026, and that her resignation was not due to any dispute or disagreement over the company’s operations or policies.
Under a Separation and General Release Agreement effective April 29, 2026, Dr. Sullivan will receive her existing salary for 18 months and may continue health coverage for up to 12 months. All of her unvested restricted stock units and stock options will vest, and the period to exercise her stock options is extended to December 31, 2030. The agreement includes a one-year post-separation non-solicitation covenant for Dr. Sullivan and a one-year mutual non-disparagement covenant.
Pyxis Oncology director Jakob Dupont received a new stock option grant. The award covers 45,867 options to buy Common Stock at an exercise price of $1.36 per share, expiring on March 24, 2036. All of these options vest 100% on the first anniversary of the grant date, contingent on his continued service. Following this grant, Dupont holds 45,867 derivative securities, reflecting a routine, compensation-related equity award rather than an open‑market trade.
Pyxis Oncology, Inc. reported that principal financial and accounting officer Jitendra Wadhane received new equity compensation awards. He was granted a stock option for 262,635 shares of common stock at an exercise price of $1.36 per share, expiring on March 24, 2036. He also received 109,461 shares of common stock in the form of restricted stock units at no cost.
The restricted stock units vest 25% on March 31, 2026, then in 36 substantially equal monthly installments, subject to continued employment. The stock option vests 25% on the first anniversary of March 24, 2026, with the remainder vesting in 36 equal monthly installments on continued employment. Following these awards, his directly held common stock position is 512,882 shares.
Pyxis Oncology, Inc. reported that director John L. Flavin received a grant of stock options covering 45,867 shares of common stock. The options have an exercise price of $1.36 per share and expire on March 24, 2036. According to the terms, 100% of these options vest on the first anniversary of the grant date, subject to his continued service, and following this grant he holds 45,867 derivative securities directly.
Pyxis Oncology director Michael A. Metzger received a grant of 45,867 stock options for Common Stock. The options have an exercise price of $1.3600 per share and expire on March 24, 2036. All 45,867 options vest 100% on the first anniversary of the grant date, contingent on his continued service.
Following this award, Metzger holds 45,867 options directly, and no open-market purchases or sales were reported in this filing.
Pyxis Oncology director Freda C. Lewis-Hall received a stock option award for 45,867 shares of common stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036. According to the filing, all 45,867 option shares will vest 100% on the first anniversary of the grant date, if she continues in service through that vesting date. Following this grant, she holds 45,867 stock options directly.
Pyxis Oncology director Darren S. Cline received a stock option grant for 45,867 shares of Common Stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036. All 45,867 option shares vest 100% on the first anniversary of the grant date, contingent on his continued service. Following this grant, Cline holds options covering 45,867 shares, and the filing shows no same-day exercises or market purchases or sales.
Pyxis Oncology, Inc. director Rachel Humphrey received a grant of stock options covering 45,867 shares of common stock. The options have an exercise price of $1.36 per share and were awarded at no cost to her.
The filing states that all 45,867 options will vest 100% on the first anniversary of the March 24, 2026 grant date, as long as she continues in service through that date. Following this award, her reported derivative holdings from this grant total 45,867 stock options.